A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
Sponsor: Novartis Pharmaceuticals
Terminated
considering the limited clinical activity observed with LTT462, the decision was made to not open the dose expansion phase of the study
Listed as NCT02711345, this PHASE1 trial focuses on Melanoma and Non-Small-Cell Lung Carcinoma and remains terminated or withdrawn. Sponsored by Novartis Pharmaceuticals, it has been updated 16 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
▶ Show 11 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
-
Oct 2019 — Nov 2020 [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
May 2019 — Oct 2019 [monthly]
Completed PHASE1
-
Apr 2019 — May 2019 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Aug 2018 — Apr 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .